4//SEC Filing
PERCEPTIVE ADVISORS LLC 4
Accession 0001062993-21-001115
CIK 0001785345other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 7:20 PM ET
Size
25.4 KB
Accession
0001062993-21-001115
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2021-02-09$13.80/sh+64,730$893,274→ 7,264,800 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$12.53/sh+86,671$1,085,988→ 7,198,299 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$14.60/sh+34,951$510,285→ 7,299,751 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$11.38/sh+34,611$393,873→ 7,111,628 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$13.10/sh+1,771$23,200→ 7,200,070 total(indirect: See footnote) - Purchase
Common Stock
2021-02-05$11.14/sh+27,453$305,826→ 7,077,017 total(indirect: See footnote)
Holdings
- 5,799,564(indirect: See footnote)
Common Stock
- 1,770,600(indirect: See footnote)
Common Stock
- 3,090,924(indirect: See footnote)
Common Stock
Xontogeny, LLC
Director
Transactions
- Purchase
Common Stock
2021-02-08$13.10/sh+1,771$23,200→ 7,200,070 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$14.60/sh+34,951$510,285→ 7,299,751 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$13.80/sh+64,730$893,274→ 7,264,800 total(indirect: See footnote) - Purchase
Common Stock
2021-02-05$11.14/sh+27,453$305,826→ 7,077,017 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$11.38/sh+34,611$393,873→ 7,111,628 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$12.53/sh+86,671$1,085,988→ 7,198,299 total(indirect: See footnote)
Holdings
- 3,090,924(indirect: See footnote)
Common Stock
- 5,799,564(indirect: See footnote)
Common Stock
- 1,770,600(indirect: See footnote)
Common Stock
PERCEPTIVE ADVISORS LLC
Director10% Owner
Transactions
- Purchase
Common Stock
2021-02-08$13.10/sh+1,771$23,200→ 7,200,070 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$14.60/sh+34,951$510,285→ 7,299,751 total(indirect: See footnote) - Purchase
Common Stock
2021-02-05$11.14/sh+27,453$305,826→ 7,077,017 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$11.38/sh+34,611$393,873→ 7,111,628 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$12.53/sh+86,671$1,085,988→ 7,198,299 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$13.80/sh+64,730$893,274→ 7,264,800 total(indirect: See footnote)
Holdings
- 5,799,564(indirect: See footnote)
Common Stock
- 1,770,600(indirect: See footnote)
Common Stock
- 3,090,924(indirect: See footnote)
Common Stock
Transactions
- Purchase
Common Stock
2021-02-09$13.80/sh+64,730$893,274→ 7,264,800 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$12.53/sh+86,671$1,085,988→ 7,198,299 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$11.38/sh+34,611$393,873→ 7,111,628 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$13.10/sh+1,771$23,200→ 7,200,070 total(indirect: See footnote) - Purchase
Common Stock
2021-02-05$11.14/sh+27,453$305,826→ 7,077,017 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$14.60/sh+34,951$510,285→ 7,299,751 total(indirect: See footnote)
Holdings
- 1,770,600(indirect: See footnote)
Common Stock
- 3,090,924(indirect: See footnote)
Common Stock
- 5,799,564(indirect: See footnote)
Common Stock
EDELMAN JOSEPH
Director
Transactions
- Purchase
Common Stock
2021-02-05$11.14/sh+27,453$305,826→ 7,077,017 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$12.53/sh+86,671$1,085,988→ 7,198,299 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$13.10/sh+1,771$23,200→ 7,200,070 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$13.80/sh+64,730$893,274→ 7,264,800 total(indirect: See footnote) - Purchase
Common Stock
2021-02-09$14.60/sh+34,951$510,285→ 7,299,751 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$11.38/sh+34,611$393,873→ 7,111,628 total(indirect: See footnote)
Holdings
- 1,770,600(indirect: See footnote)
Common Stock
- 5,799,564(indirect: See footnote)
Common Stock
- 3,090,924(indirect: See footnote)
Common Stock
Footnotes (11)
- [F1]The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.
- [F10]The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of P the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F11]The securities are directly held by Xontogeny, LLC ("Xontogeny"). C2 Ventures, LLC ("C2") is the manager of Perceptive XV Holdings, LLC ("Holdings"), the manager of Xontogeny. Joseph Edelman is the managing member of C2. Holdings, C2, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F2]These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.
- [F3]These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.
- [F4]These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.
- [F5]These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.
- [F6]These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.
- [F7]These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.
- [F8]The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the ???Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F9]The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Issuer
Landos Biopharma, Inc.
CIK 0001785345
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001224962
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 7:20 PM ET
- Size
- 25.4 KB